{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:38:52Z","timestamp":1791722332628,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.02.023","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T19:58:51Z","timestamp":1646078331000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"213","author":[{"given":"Peter Lykke","family":"Eriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Louise","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Vilstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.02.023_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0015","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3748\/wjg.v13.i10.1579","article-title":"Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease","volume":"13","author":"Hamaguchi","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0020","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","article-title":"Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients","volume":"54","author":"Targher","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.thromres.2022.02.023_bb0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0030","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/liv.15004","article-title":"Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease","volume":"41","author":"M\u00e4nnist\u00f6","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.thromres.2022.02.023_bb0035","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.cgh.2020.07.030","article-title":"Association of Hepatic Steatosis with Major Adverse Cardiovascular Events, independent of coronary artery disease","volume":"19","author":"Meyersohn","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.coph.2004.10.003","article-title":"Hypercoagulability in the metabolic syndrome","volume":"5","author":"Nieuwdorp","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0055","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"NASH clinical research network (CRN), prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.02.023_bb0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-National Cohort Study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0065","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0070","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.3748\/wjg.v16.i48.6119","article-title":"High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism","volume":"16","author":"Di Minno","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/lt.24134","article-title":"Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis","volume":"21","author":"Stine","year":"2015","journal-title":"Liver Transpl."},{"key":"10.1016\/j.thromres.2022.02.023_bb0080","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1478-3231.2010.02375.x","article-title":"Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease","volume":"31","author":"Kotronen","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.thromres.2022.02.023_bb0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2009.10.011","article-title":"Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease","volume":"209","author":"Sookoian","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2022.02.023_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.26510","article-title":"Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"59","author":"Verrijken","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/hep.24721","article-title":"Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis","volume":"55","author":"Alkhouri","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/09537104.2012.688898","article-title":"Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease","volume":"24","author":"Celikbilek","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2022.02.023_bb0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11239-013-0932-x","article-title":"Propensity for young reticulated platelet recruitment into arterial thrombi","volume":"37","author":"McBane","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2022.02.023_bb0115","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2016.06.001","article-title":"Preserved hemostatic status in patients with non-alcoholic fatty liver disease","volume":"65","author":"Potze","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jhep.2016.09.025","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"66","author":"Tripodi","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2016.10.011","article-title":"Reply to: \u201cProcoagulant imbalance in patients with non-alcoholic fatty liver disease\u201d","volume":"66","author":"Potze","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clinre.2019.01.001","article-title":"Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions","volume":"43","author":"Lykke Eriksen","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/apt.15293","article-title":"Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study","volume":"50","author":"Eriksen","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2022.02.023_bb0140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"FLIP pathology consortium, utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/aas.12885","article-title":"The effect of fresh frozen plasma in critically ill patients","volume":"61","author":"Vibede","year":"2017","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.thromres.2022.02.023_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2018.04.025","article-title":"Fibrin clot lysis assay: establishment of a reference interval","volume":"167","author":"Neergaard-Petersen","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.02.023_bb0160","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.thromres.2012.06.017","article-title":"Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry","volume":"130","author":"Rubak","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.02.023_bb0165","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cyto.b.21642","article-title":"Platelet characteristics in patients with essential thrombocytosis","volume":"94","author":"Pedersen","year":"2018","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.thromres.2022.02.023_bb0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.thromres.2022.02.023_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/mps3040067","article-title":"Fibrin clot formation and lysis in plasma","volume":"3","author":"Larsen","year":"2020","journal-title":"Methods Protoc."},{"key":"10.1016\/j.thromres.2022.02.023_bb0180","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.thromres.2022.02.023_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.2008.07569.x","article-title":"Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men","volume":"145","author":"Meltzer","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0190","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2004-08-3253","article-title":"Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis","volume":"105","author":"Lisman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.02.023_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction","volume":"2","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2022.02.023_bb0200","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/01.CIR.94.9.2057","article-title":"Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities","volume":"94","author":"Juhan-Vague","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2022.02.023_bb0205","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0049-3848(94)90262-3","article-title":"Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus","volume":"75","author":"Torr-Brown","year":"1994","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.02.023_bb0210","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1160\/th14-05-0468","article-title":"The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease","volume":"112","author":"Neergaard-Petersen","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.02.023_bb0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diab.43.1.104","article-title":"Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients","volume":"43","author":"McGill","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.thromres.2022.02.023_bb0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.283.2.221","article-title":"Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham offspring study","volume":"283","author":"Meigs","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2022.02.023_bb0225","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0026-0495(86)90209-X","article-title":"Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects","volume":"35","author":"Vague","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.thromres.2022.02.023_bb0230","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.ijo.0802778","article-title":"Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1","volume":"28","author":"Skurk","year":"2004","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.thromres.2022.02.023_bb0235","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1161\/01.ATV.0000242905.41404.68","article-title":"PAI-1 and the metabolic syndrome: links, causes, and consequences","volume":"26","author":"Alessi","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2022.02.023_bb0240","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.28287","article-title":"Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease","volume":"63","author":"Rosso","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2022.02.023_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101262","article-title":"Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance","volume":"53","author":"H\u00f6rber","year":"2021","journal-title":"Mol Metab."},{"key":"10.1016\/j.thromres.2022.02.023_bb0255","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2022.02.023_bb0260","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.thromres.2012.01.016","article-title":"Reduced clot-stability during the first 6 hours after aneurysmal subarachnoid haemorrhage\u2013a prospective case-control study","volume":"129","author":"Larsen","year":"2012","journal-title":"Thromb. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:47:06Z","timestamp":1758736026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":52,"alternative-id":["S0049384822000676"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.023","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}